LZTS2 Antibody | 5073

LZTS2 Antibody | 5073 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: Predicted species reactivity based on immunogen sequence: Bovine: (94%) , Mouse: (88%) , Rat: (82%)

Immunogen: LZTS2 antibody was raised against a 17 amino acid synthetic peptide near the carboxy terminus of human LZTS2.
The immunogen is located within amino acids 570 - 620 of LZTS2.

Research Area: Cancer, Cell Cycle

Tested Application: E, IHC-P

Application: LZTS2 antibody can be used for detection of LZTS2 by immunohistochemistry at 5 μg/mL.
Antibody validated: Immunohistochemistry in human samples. All other applications and species not yet tested.

Specificiy: LZTS2 antibody is predicted to not cross-react with other LZTS family members.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: LZTS2 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: LZTS2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: LZTS2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: LZTS2 Antibody: LAPSER1, KIAA1813, LAPSER1, Leucine zipper putative tumor suppressor 2, Protein LAPSER1, hLZTS2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: LZTS2 Antibody: The leucine zipper putative tumor suppressor 2 (LZTS2, also known as LAPSER1) , a member of the LZTS family, is a negative regulator of the Wnt signaling pathway. It represses beta-catenin-mediated transcriptional activation by promoting the nuclear exclusion of beta-catenin. LZTS2 is involved in cytokinesis and regulates katanin-mediated microtubule severing and release from the centrosome. LZTS2 may negatively regulate axonal outgrowth by preventing the formation of microtubule bundles that are necessary for transport within the elongating axon. LZTS2 is highly expressed in testis and prostate, but it is deleted in multiple cancers, including prostate tumors, suggesting that LZTS2 acts as a potential tumor suppressor.